Immunocore Limited announced the appointment of Christina Coughlin as Chief Medical Officer. Dr. Coughlin will be responsible for providing medical and regulatory leadership to the pre-clinical and clinical programmes for the company. Most recently, Dr. Coughlin was leading two early development programmes at Novartis in checkpoint inhibition
and PI3'kinase inhibition.